» Articles » PMID: 24498052

Inhibition of Nucleotide Biosynthesis Potentiates the Antifungal Activity of Amphotericin B

Overview
Journal PLoS One
Date 2014 Feb 6
PMID 24498052
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The polyene antifungal agent Amphotericin B exhibits potent and broad spectrum fungicidal activity. However, high nephrotoxicity can hinder its administration in resource poor settings. Quantification of early fungicidal activity in studies of HIV patients with cryptococcosis demonstrate that 5-Fluorocytosine therapy in combination with Amphotericin B results in faster clearance than with Amphotericin B alone. In vitro synergy between the two drugs has also been reported but the mechanism by which 5-Fluorocytosine synergizes with Amphotericin B has not been delineated. In this study we set out to investigate the effect of genetic mutation or pharmacologic repression of de novo pyrimidine and purine biosynthesis pathways on the Amphotericin B susceptibility of Cryptococcus neoformans. We demonstrate that a ura- derivative of wild type Cryptococcus neoformans strain H99 is hypersensitive to Amphotericin B. This sensitivity is remediated by re-introduction of a wild type URA5 gene, but not by addition of exogenous uracil to supplement the auxotrophy. Repression of guanine biosynthesis by treatment with the inosine monophosphate dehydrogenase inhibitor, mycophenolic acid, was synergistic with Amphotericin B as determined by checkerboard analysis. As in Cryptococcus neoformans, a ura(-) derivative of Candida albicans was also hypersensitive to Amphotericin B, and treatment of Candida albicans with mycophenolic acid was likewise synergistic with Amphotericin B. In contrast, neither mycophenolic acid nor 5-FC had an effect on the Amphotericin B susceptibility of Aspergillus fumigatus. These studies suggest that pharmacological targeting of nucleotide biosynthesis pathways has potential to lower the effective dose of Amphotericin B for both C. neoformans and C. albicans. Given the requirement of nucleotide and nucleotide sugars for growth and pathogenesis of Cryptococcus neoformans, disrupting nucleotide metabolic pathways might thus be an effective mechanism for the development of novel antifungal drugs.

Citing Articles

Discovery of CO tolerance genes associated with virulence in the fungal pathogen Cryptococcus neoformans.

Chadwick B, Ristow L, Xie X, Krysan D, Lin X Nat Microbiol. 2024; 9(10):2684-2695.

PMID: 39232204 DOI: 10.1038/s41564-024-01792-w.


Comparative analysis of the biological characteristics and mechanisms of azole resistance of clinical strains.

Zeng M, Zhou X, Yang C, Liu Y, Zhang J, Xin C Front Microbiol. 2023; 14:1253197.

PMID: 38029222 PMC: 10665732. DOI: 10.3389/fmicb.2023.1253197.


Antifungal Activity of Sodium New Houttuyfonate Against and .

Zhang Q, Liu F, Zeng M, Zhang J, Liu Y, Xin C Front Microbiol. 2022; 13:856272.

PMID: 35558127 PMC: 9087332. DOI: 10.3389/fmicb.2022.856272.


Drug repurposing strategies in the development of potential antifungal agents.

Zhang Q, Liu F, Zeng M, Mao Y, Song Z Appl Microbiol Biotechnol. 2021; 105(13):5259-5279.

PMID: 34151414 PMC: 8214983. DOI: 10.1007/s00253-021-11407-7.


Synthetic Derivatives of Ciclopirox are Effective Inhibitors of .

Lin J, Zangi M, Narayana Hajay Kumar T, Reddy M, Raghava Reddy L, Sadhukhan S ACS Omega. 2021; 6(12):8477-8487.

PMID: 33817509 PMC: 8015083. DOI: 10.1021/acsomega.1c00273.


References
1.
. Pyrimidine biosynthesis in Saccharomyces cerevisiae: the ura2 cluster gene, its multifunctional enzyme product, and other structural or regulatory genes involved in de novo UMP synthesis. Biochem Cell Biol. 1989; 67(9):612-31. DOI: 10.1139/o89-094. View

2.
Miceli M, Diaz J, Lee S . Emerging opportunistic yeast infections. Lancet Infect Dis. 2011; 11(2):142-51. DOI: 10.1016/S1473-3099(10)70218-8. View

3.
Panepinto J, Komperda K, Hacham M, Shin S, Liu X, Williamson P . Binding of serum mannan binding lectin to a cell integrity-defective Cryptococcus neoformans ccr4Delta mutant. Infect Immun. 2007; 75(10):4769-79. PMC: 2044520. DOI: 10.1128/IAI.00536-07. View

4.
Ittarat I, Asawamahasakda W, Bartlett M, Smith J, Meshnick S . Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995; 39(2):325-8. PMC: 162535. DOI: 10.1128/AAC.39.2.325. View

5.
Moyrand F, Janbon G . UGD1, encoding the Cryptococcus neoformans UDP-glucose dehydrogenase, is essential for growth at 37 degrees C and for capsule biosynthesis. Eukaryot Cell. 2004; 3(6):1601-8. PMC: 539039. DOI: 10.1128/EC.3.6.1601-1608.2004. View